Literature DB >> 29539608

Improved Production of Highly Active and Pure Human Creatine Kinase MB.

Sureyya Mert Selimoglu1, Murat Kasap1, Gurler Akpinar1, Aynur Karadenizli2, Abdul Mounem Wis3, Uzay Gormus4.   

Abstract

Human creatine kinase MB (hCKMB) is one of the most preferred biomarkers used for the diagnosis of acute coronary syndrome due to its high sensitivity and specificity. The increasing need for highly purified and biologically active hCKMB in the field of diagnostics makes its production valuable. Currently, the production of hCKMB is mainly achieved in methylotrophic yeast, Pichia pastoris, because the production in Escherichia coli is challenging and generally yields an inactive enzyme with a low quantity. With the aim of finding the best way for the high-yield production of active hCKMB in E. coli, an efficient strategy was developed using a construct allowing tandem expression of each subunit with 2 different tags. The strategy allowed the efficient expression and separate characterization of each subunit and 1-step purification of the heterodimeric protein into homogeneity. The heterodimeric protein displayed more than 11-fold greater specific activity than the commercially available one. The production strategy described in this study shows a clear advantage over the currently used ones and can be made available not only for laboratory scale production but also for commercial production. Our study is also a well-suited example for the studies in which novel protein expression strategies are needed to achieve greater yields with higher purities.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Escherichia coli; Human creatine kinase MB; Protein engineering; Protein modeling

Mesh:

Substances:

Year:  2018        PMID: 29539608     DOI: 10.1159/000486716

Source DB:  PubMed          Journal:  J Mol Microbiol Biotechnol        ISSN: 1464-1801


  1 in total

1.  Changes in humoral immunity, myocardial damage, trace elements, and inflammatory factor levels in children with rotavirus enteritis.

Authors:  Peihui Liu; Rong Zou; Jie Zhao; Jindou Hao; Yongmei Zeng; Wanqu Liu; Jia Tian; Hao Wang
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.